Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

NCT05410847 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Camrelizumab Nab-Paclitaxel S-1

Sponsor

Hebei Medical University